The Epilepsy Society says the sale would raise about £93m, which will fund research.

EpilepsyGTx, a biotechnology company developing cutting-edge gene therapies to treat refractory epilepsy, and ClearPoint ...

Epilepsy affects more than 50 million people worldwide, making it one of the most common neurological disorders. Although ...

Epilepsy medication helped the golden retriever, but it dulled her personality. The arrival of a 4-day-old duckling sparked ...

Emerging biomarkers and genetic profiles may help identify patients with high risk for sudden epileptic death.

Neuroelectrics is developing therapies that it says will improve the lives of people living with brain disease. The Barcelona-based start-up's main product is a headcap, which monitors the brain's ...

In patients with newly diagnosed epilepsy, nearly 70% of seizure relapses are linked to potentially modifiable factors, including poor adherence and inadequate ASM dosing, rather than drug resistance.

A drug commonly used to treat epilepsy could be repurposed to significantly boost the response to vaccines in humans, helping ...

On Saturday, the Epilepsy Foundation of Michigan will return to Frederik Meijer Gardens & Sculpture Park for its 25th annual ...

As the EU turns global brain health commitments into national action, member states remain far apart on epilepsy care ...